Lucia Masarova, MD

Lucia Masarova, MD, PhD, discusses some of the latest updates across myeloproliferative neoplasms.

Lucia Masarova, MD, PhD, discusses the rationale of the EXCEED-ET study of ropeginterferon alfa-2b-njf for patients with essential thrombocytopenia.

Lucia Masarova, MD, PhD, discusses therapeutic options for patients with polycythemia vera who are refractory to hydroxyurea.

Lucia Masarova, MD, discusses available treatment options for patients with essential thrombocythemia.

Lucia Masarova, MD, discusses the efficacy of CPI-0610 in the phase 2 MANIFEST trial in patients with myelofibrosis.

The researchers discuss the rationale for checkpoint-based therapies including antibodies to PD-1/PD-L1 and CTLA-4, an overview of clinical experience with these agents, and future considerations and combinations of these agents.